Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2947 Al18F-NOTA-Octreotide PET Imaging of the Somatostatin Receptor: First Comparison with 68Ga-DOTATATE in Neuroendocrine Tumor Patients

Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K,

Keywords: neuroendocrine tumors, PET, Al18F-NOTA-octreotide, 68Ga-DOTATATE, somatostatin receptor imaging,

#2787 64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast

Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Loft M, Johannesen H, Carlsen E, Johnbeck C, Binderup T,

Keywords: 64Cu-DOTATATE, Neuroendocrine Neoplasms, PET Imaging, Somatostatin Receptor Imaging,

#2717 64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms

Introduction: The degree of overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) may reflect tumor differentiation and thus be associated with prognosis. Non-invasive quantification of receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carlsen E

Authors: Carlsen E, Johnbeck C, Binderup T, Loft M, Pfeifer A,

Keywords: 64Cu-dotatate, neuroendocrine neoplasm, progression-free survival, overall survival,

#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, Severi S, Drozdov I, Nicolini S,

Keywords: NETest, PRRT,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.